BridgeBio Oncology Therapeutics, Inc. (BBOT)
Score window: May. 30, 2025 to May. 29, 2026
| Date | Form | Sentiment | Urgency | Summary | Open |
|---|---|---|---|---|---|
| Sep. 8, 2025 | CORRESP | Neutral/Informational | Moderate | BridgeBio Oncology Therapeutics, Inc. has submitted a request for the acceleration of the effective date of its Registration Statement on Form S-1. The company aims for the regist… | Read Filing EDGAR |
| Sep. 3, 2025 | UPLOAD | Neutral/Informational | Low | The SEC has communicated to BridgeBio Oncology Therapeutics, Inc. that they will not review the company's registration statement filed on August 29, 2025. The SEC emphasizes that … | Read Filing EDGAR |
| Jul. 9, 2025 | CORRESP | Neutral/Informational | Moderate | The correspondence is a formal request from Helix Acquisition Corp. II and TheRas, Inc. to the SEC for the acceleration of their Registration Statement on Form S-4. They are seeki… | Read Filing EDGAR |
| Jul. 1, 2025 | CORRESP | Neutral/Informational | Moderate | The correspondence is a response from Helix Acquisition Corp. II and TheRas, Inc. to comments from the SEC regarding their Registration Statement on Form S-4. The letter addresses… | Read Filing EDGAR |
| Jun. 27, 2025 | UPLOAD | Concern from SEC | High | The SEC has reviewed the registration statement for Helix Acquisition Corp. II and TheRas, Inc. and provided comments that require a response. Key issues include the NTBV calculat… | Read Filing EDGAR |
| Jun. 20, 2025 | CORRESP | Neutral/Informational | Moderate | The correspondence from BridgeBio Oncology Therapeutics, Inc. and Helix Acquisition Corp. II addresses comments from the SEC regarding their Draft Registration Statement on Form S… | Read Filing EDGAR |
| Jun. 11, 2025 | UPLOAD | Concern from SEC | High | The SEC has reviewed the amended draft registration statement for Helix Acquisition Corp. II and TheRas, Inc. and has provided comments that require a response. Key issues include… | Read Filing EDGAR |